Skip to Content


In the US, Gadoteridol (gadoteridol systemic) is a member of the drug class magnetic resonance imaging contrast media and is used to treat CNS Magnetic Resonance Imaging.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Contrast medium for NMR-tomography

Chemical Name

Gadolinium, (±)-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)]-

Foreign Names

  • Gadoteridolum (Latin)
  • Gadoteridol (German)
  • Gadoteridol (French)
  • Gadoteridol (Spanish)

Generic Names

  • Gadoteridol (OS: USAN, BAN, JAN)
  • Gd-HP-DO 3A (IS)
  • SQ 32692 (IS: Squibb)
  • Gadoteridol (PH: USP 38)

Brand Names

  • ProHance
    Bracco, Belgium; Bracco, Denmark; Bracco, France; Bracco, Italy; Bracco, Sweden; Bracco Imaging, Germany; Bracco Imaging, Finland; Bracco Imaging, Norway; Bracco Imaging, Poland; Bracco Imaging Italia, Austria; Bracco Suisse, Switzerland; Bracco UK, United Kingdom; Bracco-Altana Pharma, Netherlands; Eisai, Japan; Rovi, Spain


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.